



Information session for the National Reference Center for Borrelia burgdorferi (UCL St Luc and UZ Leuven)

16-11-2023

Benoît Kabamba Mukadi

Melissa Depypere & Lize Cuypers



Recap important information

- Accreditation requested: please enter your name (and RIZIV/INAMI if applicable) in the chat box
- Interactive sessions: you can speak up by unmuting your microphone to ask questions or raise comments in the chat box
- No recording of the session but slides will be shared <u>https://www.uzleuven.be/nl/laboratoriumgeneeskunde/nationale-referentiecentra-en-</u> <u>referentielaboratoria</u> <u>https://www.sciensano.be/nl/nrc-nrl/nationaal-referentiecentrum-nrc-voor-borrelia-burgdorferi-</u> <u>lymeziekte</u>





NRC Lyme Borreliosis



Université Catholique de Louvain

UZ Leuven (associated)







Available tests



UCL St Luc and UZ Leuven

- Diagnosis by serology: Borrelia (serum) and neuroborreliosis (CSF)
- Confirmation by serology: Borrelia (serum) and neuroborreliosis (CSF)

UCL St Luc only

- Molecular diagnostics and identification of Borrelia (species)
- Culture and direct examination (studies)

UZ Leuven only

• CXCL13 biomarker (CSF) in the context of acute neuroborreliosis



NRC for Borrelia burgdorferi (Lyme's disease)





Nationaal Referentiecentrum (NRC) voor Borrelia burgdorferi (Lymeziekte)

Belangrijk bericht

De tests moeten aangevraagd worden met het volledig ingevuld NRC-formulier met aanwijzing van de klinische en anamnestische redenen. Indien geen enkele serologische of andere bevestiging gevraagd wordt, zullen alle tests uitgevoerd door het NRC als onderaanneming beschouwd worden en zal betaling volgens de normale RIZIV-procedure gevraagd worden.

Meer informatie?

Voor meer informatie betreffende de werking van het NRC Borrelia burgdorferi (Lymeziekte) kan u de volgende website contacteren: https://uclouvain.be/fr/instituts-recherche/irec/mblg@

Nuttige links:

Onderaan deze pagina kan u de **NRC-rapporten** terugvinden.

De bijhorende epidemiologische surveillance-rapporten kan u consulteren via:

Gezondheidsonderwerp Ziekte van Lyme 💡 Gezondheidsonderwerp Tekenoverdraagbare ziekten

Gezondheidsonderwerp Vectoroverdraagbare ziekten



Borrelia burgdorferi (Ziekte van Lyme)

Verantwoordelijke laboratoria

Coördinator

• Université Catholique de Louvain

Geassocieerd

• UZ Leuven/KU Leuven

Erkend door

• National Institute for Health and Disability Insurance (INAMI-RIZIV)

Aanvraagformulieren

• Aanvraagformulier Borrelia



Scientific reports (including NRC data)





Nuttige links:

Onderaan deze pagina kan u de NRC-rapporten terugvinden.

De bijhorende epidemiologische surveillance-rapporten kan u consulteren via:

Gezondheidsonderwerp Ziekte van Lyme 🍃 Gezondheidsonderwerp Tekenoverdraagbare ziekten

Gezondheidsonderwerp Vectoroverdraagbare ziekten

Epidemiologische surveillance van Lyme borreliose - 2019-2021



Auteurs

inne Lernout; Cuypers, Lize; Sherihane Bensemmane; Dessilly, Géraldine; Scohy, Annaïs; Lagrou, Katrien; Depypere, Melissa; Kabamba-Mukadi, Benoît



Nationalité :

Nº national :

Application form



Borrelia burgdorferi

L'ÉCHANTILLON	
Nom du laboratoire :	
Biologiste responsable :	
Tél. : Fax :	
Adresse email :	Date
Médecin prescripteur :	Symp
	Ery
N° INAMI :	
	Ne
	🗖 Au
RENSEIGNEMENTS CONCERNANT LE PATIENT	Spéc
*Nom/prénom :	
*Sexe : 🛛 H 🖓 F	
*Date de naissance (ou âge) :	🗆 Mo
*Adresse :	Pro
*Code postal/Localité :	DT

*IDENTIFICATION DU LABORATOIRE OUI ENVOIE

RENSEIGNEMENTS CONCERNANT L'ÉCHANTILLON

*Numéro d'identification :				
*Nature :				
*Date de prélèvement :				
Tests effectués par le laboratoire demandeur ? 🗆 Oui 📮 Non				
Nom test 1:				
Résultat :				
Nom test 2 :				
Résultat :				
IgG totales ou protéines LCRg/L Sérumg/L				
* Renseignements indispensables ** Requis pour le financement dans le cadre des CNR+** Pour les tests de sérologie, si demande				
en 1 ⁱⁿ ligne, les tests seront remboursés par la nomenclature de l'INAMI				
****Matrices en cours de validation				
EFFECTIF A PARTIR DU 28/10/2021				

RESPONSABLE DU DOCUMENT : A. BUCHELOT

CADRE RÉSERVÉ AU CENTRE DE RÉFÉRENCE *INFORMATIONS CLINIQUES de début des symptômes :.... ptômes : ythema migrans rthrite euroborréliose :.....cellules/uL ;% Lymphocytes utres. cifiez : *INFORMATIONS ÉPIDÉMIOLOGIQUES orsure de tique. Date : ovince probable de contamination : Traitement avant prélèvement diagnostique. Borréliose préalable. Année : Autres données épidémiologiques : . ANALYSES DEMANDÉES Sérologie diagnostique*** Borrelia IgG (SANG) Borrelia IgM (SANG) Borrelia IgG (LCR) Sérologie de confirmation (Immunoblot)*** Borrelia Confirmation IgG (SANG) Borrelia Confirmation IgM (SANG) Borrelia Confirmation IgG (LCR) Borrelia Confirmation IgM (LCR) DPCR - Diagnostic et typage moléculaire (LCR, liquide articulaire, peau**** ou biopsie articulaire**** non fixée)

Dosage CXCL13 dans LCR (à envoyer directement à UZLeuven)

Analyse réalisée par un sous-traitant :

16SADN2E PCR 16s - Fièvre récurrente (B. recurrentis, B. miyamotoi, B. hispanica, ...sur sang total EDTA)

*GEGEVENS OVER HET LABORATORIUM DAT HET STAAL OPSTUURT	VOORBEHOUDEN VOOR HET REFERENTIECENTRUM
Naam laboratorium:	
Klinische Bioloog:	
Tel: Fax:	
Emailadres:	*KLINISCHE GEGEVENS
	Datum van aanvang symptomen :
Aanvragende arts :	Symptomen:
	Erythema migrans
RIZIV n° :	C Artritis
	Neuroborreliose:cellen/ul;% Lymfocyten
PATIENTGEGEVENS (OF STICKER)	Andere, specificeer:
*Naam/voornaam:	
*Geslacht: IM IV	
*Geboortedatum (of leeftijd):	*EPIDEMIOLOGISCHE GEGEVENS
*Adres:	Tekenbeet, Datum :
*Postcode of woonplaats:	
Nationaliteit:	Vermoedelijke provincie van besmetting :
Rijksregister n°	Behandeling reeds gestart voor staalname.
	Vroegere Lyme borreliose. Jaar :
	Andere epidemiologische gegevens :
GEGEVENS OVER HET STAAL	
*Identificatienummer:	
* Staaltype:	AANGEVRAAGDE TESTEN***
*Afnamedatum:	Serologie – diagnose
TESTEN IN HET AANVRAGEND LABORATORIUM	2315 Description Borrelia antistoffen (BLOED)
UITGEVOERD? 🛛 Ja 🗖 Neen	2434 Derrelia antistoffen (CSV)
Naam test 1:	Serologie – bevestiging (Immunoblot)
Resultaat:	2318 Dorrelia Confirmatie IgG (BLOED)
Naam test 2:	2319 Dorrelia Confirmatie IgM (BLOED)
	2437 Derrelia Confirmatie IgG (CSV)
Resultaat:	2438 Borrelia Confirmatie IgM (CSV)
* Verplicht in te vullen ** Vereist voor financiering in het kader NRC	Dosering CXCL13
*** Als er geen test is uitgevoerd, zullen de tests worden	2439 CXCL13 biomerker (CSV)
terugbetaald door RIZIV nomenclatuur behalve PCR en CXCL13. PCR en CXCL13 worden niet aangerekend.	PCR - Moleculaire diagnostiek en typering
****Matrix wordt gevalideerd	(CSV, gewrichtsvocht, niet gefixeerde huid**** of gewrichtsbiopt****) (Rechtstreeks naar UCLouvain verzenden)
	PCR 16s – Febris recurrens (B. recurrentis, B. miyamotoi, B.

hispanica, ... op vol bloed)

(Rechtstreeks naar UCLouvain verzenden)

INTRODUCTION



First, a little history...



In 1975... in "Old Lyme", a small town in Connecticut / USA.

"Epidemic" of asymmetric arthritis of the large joints in 39 children and 12 adults. 13 patients had noticed an annular skin lesion of increasing diameter over the preceding weeks.

The maximum frequency was observed in summer and early autumn.

Lyme disease was born. (But the Swedes had described chronic erythema migrans as early as 1909)



The beginning of the end of the story...





1982 : Mr. Burgdorfer discovered the presence of spirochetes in the intestine of an *Ixodes*



UCLouvain

Vector: arthropods of the Ixodidae family





UCLouvain


Hovious et coll. 2007

Lyme borreliosis in Belgium: transmission

- Different factors influence the risk of transmission
 - Duration of blood meal on host (12-24 hours)
 - Density of ticks in the environment
 - Prevalence of Borrelia infection in ticks (10%)
 - Climatic conditions, type of vegetation
 - Host behavior
- Final risk after bite <3%



Stages of infection – clinical manifestations








EPIDEMIOLOGY



Lyme borreliosis: seasonal variability

 The majority of cases are recorded in summer and early autumn (from June to October)




Monthly number of positive serological results for *B. burgdorferi s.l.* reported in 2018 and average over the previous 3 years (2015-2017), Belgium (Source: network of sentinel laboratories) **DCLOUVAIN**


Lyme borreliosis in Belgium: epidemiology

- The number of positive serological tests is mainly reported
 - Network of sentinel laboratories covering 67% of tests
 - National Reference Center for Borreliosis
- The serology positivity rate remains stable (2 to 3%, 2007-2015).

Figure <u>1</u>: Nombre hebdomadaire de tests sérologiques positifs pour <u>Borrelia</u> effectués par les laboratoires vigies, Belgique, 2000-2015, WIV-ISP



http://organesdeconcertation.sante.belgique.be/fr/documents/recommandations-borreliose-de-lyme-2017



Reported incidence of positive serological results for B. burgdorferi s.l. by municipality, Belgium, 2018 (Source: sentinel laboratory network)




- Epidemiological surveillance based on clinical data
 - Number of patients consulting for EM (one-off studies),
 - Number of hospitalizations for Lyme borreliosis.
- In 2003-2004 and 2008-2009, study of the network of medical monitors
 - Tick bite 18.6 per 10,000 people
 - Erythema migrans 8.3 and 9.0 per 10,000 people
 - 7,360 to 9,270 cases of ME in 2003 and 8,080 to 10,003 cases in 2009, difference not statistically significant.
- In 2015-2016, the number of consultations
 - Erythema migrans 10.6 (95% Cl 9.5-11.9) per 10,000 people
 - (WIV-ISP, D. Vancauteren, personal communication)




- From 1999 to 2010, an average of 300 people hospitalized per year
- Three sources indicate stability over the past 10 years.

Figure 4: Nombre d'hospitalisations pour maladie de Lyme (ICD9) de 2004-2013, RHM, Belgique, WIV-ISP







Reported incidence of positive serological results for *B. burgdorferi s.l.* by age group, Belgium, 2018 (Source: sentinel laboratory network)



Stability in the number of cases linked to Lyme disease over the last 10 years (even if apparent peak in 2013) but other approaches are necessary in terms of epidemiological surveillance.



Lyme borreliosis in Belgium: tick bite report (tiquesnet.be) January - December 2022




Figure 2 presents the geographical distribution of the number of tick bites per 100,000 inhabitants, established on the basis of the municipality where the bite took place.


https://tiquesnet.wiv-isp.be/results

UCLouvain


Lyme borreliosis in Belgium:

Positive tests (2018) and tick bite locations (2020) per 100,000 inhabitants

Reported incidence of positive serological results for B. burgdorferi s.l. by municipality, Belgium, 2018 (Source: surveillance laboratory network)



Geographical distribution of tick bites per 100,000 inhabitants, by municipality in Belgium, January-December 2022 (Source: https://tiquesnet.sciensano.be/results)





Lyme borreliosis in Belgium: Tick bite report (tiquesnet.be) 2022




Figure 3: Distance between the location of the bite and the place of residence in 2022

UCLouvain

Lyme borreliosis in Belgium: Tick bite report (tiquesnet.be) 2022




Figure 4: Proportion of tick bite notifications by environment

type



Lyme borreliosis in Belgium: Tick bite report (tiquesnet.be) 2016 - 2022




Figure 5: Number of bites per month, 2016 – 2022

UCLouvain


Province (nombre de tiques analysées)	Pourcentage de tiques infectées par agent pathogène 2021 (intervalle de confiance à 95 %)							
	Borrelia burgdorferi s.l.	Anaplasma phagocytop hilum	Borrelia miyamotoi	Neoehrlichia mikurensis	Babesia spp.	Rickettsia helvetica		
Bruxelles (n = 8)	12,5 % (1,7-53,7)	0 %	0 %	0 %	0 %	12,5 % (1,7-53,7)		
Anvers (n = 107)	13,1 %	2,8 %	4,7 %	4,7 %	1,9 %	16,8 %		
	(7,9-20,9)	(0,9-8,3)	(2-10,7)	(2-10,7)	(0,5-7,2)	(10,9-25,1)		
Limbourg (n = 91)	14,3 %	5,5 %	2,2 %	6,6 %	3,3 %	17,6 %		
	(8,5-23,1)	(2,3-12,5)	(0,6-8,4)	(3-13,9)	(1,1-9,7)	(11,1-26,8)		
Brabant flamand (n = 108)	7,4 %	3,7 %	2,8 %	2,8 %	0,9 %	9,3 %		
	(3,7-14,1)	(1,4-9,5)	(0,9-8,3)	(0,9-8,3)	(0,1-6,3)	(5,1-16,4)		
Flandre orientale (n = 121)	8,3 %	8,3 %	3,3 %	1,7 %	0,8 %	14,9 %		
	(4,5-14,7)	(4,5-14,7)	(1,2-8,5)	(0,4-6,4)	(0,1-5,6)	(9,6-22,4)		
Flandre occidentale (n = 50)	6 % (1,9-17)	0 % (0-7,1)	0 %	0 %	0 %	16 % (8,2-28,9)		
Flandre (n = 477)	10,1 %	4,6 %	2,9 %	3,4 %	1,5 %	14,7 %		
	(7,7-13,1)	(3,1-6,9)	(1,7-4,9)	(2,1-5,4)	(0,7-3)	(11,8-18,1)		
Brabant wallon (n = 77)	13 %	1,3 %	2,6 %	2,6 %	2,6 %	6,5 %		
	(7,1-22,5)	(0,2-8,6)	(0,7-9,8)	(0,7-9,8)	(0,7-9,8)	(2,7-14,7)		
Liège (n = 110)	9,1 % (5-16,1)	7,3 % (3,7-13,9)	2,7 % (0,9-8,1)	4,5 % (1,9-10,5)	0 %	11,8 % (7-19,3)		
Luxembourg (n = 104)	6,7 %	6,7 %	2,9 %	3,8 %	1 %	16,3 %		
	(3,2-13,5)	(3,2-13,5)	(0,9-8,6)	(1,5-9,8)	(0,1-6,5)	(10,4-24,7)		
Namur (n = 61)	18 % (10,3-29,7)	1,6 % (0,2-10,7)	3,3 % (0,8-12,2)	0 %	1,6 % (0,2-10,7)	6,6 % (2,5-16,2)		
Hainaut (n = 54)	5,6 % (1,8-15,9)	3,7 % (0,9-13,6)	1,9 % (0,3-12)	0 %	5,6 % (1,8-15,9)	13 % (6,3-24,8)		
Wallonie (n = 406)	10,1 %	4,7 %	2,7 %	2,7 %	1,7 %	11,3 %		
	(7,5-13,4)	(3-7,2)	(1,5-4,8)	(1,5-4,8)	(0,8-3,6)	(8,6-14,8)		
Total* (n = 928)	9,9 % (8,2-12)	4,7 % (3,5-6,3)	2,9 % (2-4,2)	2,9 % (2-4,2)	1,5 % (0,9-2,5)	13,3 % (11,2-15,6)		

UCLouvain





The causative agent: Borrelia burgdorferi sensu lato



Vector: Ixodes

Review

CellPress

Borrelia miyamotoi: a widespread tick-borne relapsing fever spirochete

Alex Wagemakers¹, Pieter J. Staarink¹, Hein Sprong², and Joppe W.R. Hovius^{1,3,4}

¹ Center for Experimental and Molecular Medicine, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands

² Laboratory for Zoonoses and Environmental Microbiology, National Institute for Public Health and Environment (RIVM), Antonie van Leeuwenhoeklaan 9, PO Box 1, Bilthoven, The Netherlands

³ Department of Internal Medicine, Division of Infectious Diseases, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands

⁴ Amsterdam Multidisciplinary Lyme Center, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands

Borrelia miyamotoi is a relapsing fever spirochete that has only recently been identified as a human pathogen. Borrelia miyamotoi is genetically and ecologically distinct from Borrelia burgdorferi sensu lato, while both are present in *lxodes* ticks. Over 50 patients with an acute febrile illness have been described with a *B. miyamotoi* infection, and two infected immunocompromised patients developed a meningoencephalitis. Seroprevalence studies indicate exposure in the general population and in specific risk groups, such as patients initially suspected of having human granulocytic anaplasmosis. Here, we review the available literature on *B. miyamotoi*, describing its presence in ticks, reservoir hosts, and humans, and discussing its potential impact on public health.

Borrelia miyamotoi is a relapsing fever spirochete present in *Ixodes* ticks

Glossary

Babesiosis: human tick-borne disease caused by *Babesia* parasites. *Borelia burgdorferi* s.l.: phylogenetic clade comprising at least 19 species transmitted by *Ixodes* ticks, with distinct geographic locations. Lyme borreliosis is caused by at least eight different genospecies, including *B. burgdorferi* sensu stricto in North America, and *Borrelia afzelii* and *Borrelia garinii* in Europe.

Erythema migrans (EM): expanding erythematous skin lesion, often the primary symptom of Lyme borreliosis.

Glycerophosphodiester phosphodiesterase (GlpQ): antigenic protein in TBRF spirochetes (absent in *B. burgdorferi* s.l.).

Human granulocytic anaplasmosis (HGA): tick-borne disease caused by Anaplasma phagocytophilum.

Human monocytotropic ehrlichiosis (HME): tick-borne disease caused by Ehrlichia chaffeensis.

Ixodes ticks: hard ticks, including *Ixodes scapularis* (deer tick) in North America, *Ixodes* ricinus (sheep tick) in Europe, and *Ixodes persulcatus* (taiga tick) in Asia. *Ixodes* ticks have three stages (larva, nymph, and adult) and molt into a successive stage after a blood meal that lasts several days. *Ixodes* ticks are able to transmit several pathogens to humans.


Lyme borreliosis: disease caused by B. burgdorferi s.l. that often presents with

UCLouvain

Trends Parasitol. 2015 Jun;31(6):260-9. doi: 10.1016/j.pt.2015.03.008.

Borrelia associated with relapsing fevers (B.recurrentis) giemsa staining


Detection in blood by giemsa staining or by PCR targeting 16s gene






Wilting et al. Euro Surveill. 2015

The causative agent: Borrelia burgdorferi sensu lato



Lyme borreliosis : diagnostic tests



Trevisan et al. Front. Med., 23 July 2020

Lyme borreliosis in Belgium: diagnostic tests

- Clinical and epidemiological data are essential
- Serology is the preferred diagnostic method
 - Useful in later stages of the disease
 - Reflects the immune response, humoral and cellular
 - Measures immunity, not disease activity
 - One should take this into account when interpreting serological results.
- Performance depends on the Ag(s) set(s)
 - Recombinants
 - C6 or VIsE for IgG and OspC for IgM
 - IgM to be interpreted only within 6 to 8 weeks following exposure



Direct diagnosis: Molecular testing

	Erythème	e migrant	nt Méningoradiculites Formes compliquées précoces		Arthrites		Acrodermatite chronique atrophiante ACA	
	Serum	peau	Serum	LCR	Serum	Liquide* articulaire	Serum	Peau
Culture	NR	38-80%	NR	≤10%	NR	<5%	NR	20-60%
PCR	NR	60-90%	NR	25%	NR	50-70%	NR	60-90%
ELISA	20-50%	NR	70-90%	50-90%	90-100%	NR	95-100%	NR

NR : non réalisable * : meilleurs résultats avec les biopsies synoviales

.

Dr Marc V Assous- Hopital Cochin

Sensitivity increases over time



• · · · ·

Direct diagnosis: Molecular testing

- PCR can help with diagnosis, as a complementary test to serology:
 - In case of skin and joint manifestations
 - In EM, the sensitivity is about 68%
 - Regarding fluid and joint biopsy the sensitivity is 76-85%
 - Each doubtful or positive result is confirmed by sequencing, thus allowing a specificity of 100%
- PCR has little place in neurological manifestations
 - Sensitivity is between 10 to 50%
 - The index of intrathecal antibody synthesis is more sensitive (+ CXCL13)
- The diagnostic value of PCR for blood/serum/plasma or urine is not established and the test is not recommended.



Direct diagnosis: Molecular testing

Type of test	Purpose of the test	Number of test	Positive PCR	Doubtful PCR	B.afzelii	B.burgdorferi	B.garinii	B.sp
PCR Borrelia flagelline or OspA	Confirmation of diagnosis	1 755	56 (3,2%)	98 (5,6%)				
SEQ Borrelia flagelline or OspA	Species identification	41 (2,3%)	29 (1,7%)	11 (0,6%)	11 (0,6%)	14 (0,8%)	8 (0,5%)	8 (0,5%)
5S-23S rDNA Real Time PCR	Detection of infected ticks, Borrelia species determination (epidemiology, strain collection)							
Borrelia culture	Diagnosis							

Data from 2018 to 2022: the vast majority of positive PCRs are articular fluids, almost no CSF.




Direct diagnosis: bacterial culture

- Culture
- has a sensitivity between 40 and 80% for skin biopsies, articular fluids
- Very low: 1.2-13% for blood and CSF,
- Culture on specific BSK medium (liquid)
- Lasts 2 to 6 weeks
- Demand for this test is very low.



 Direct fresh examination or after staining has very low sensitivy





Direct diagnosis: bacterial culture

	burgdorferi se	ensu lato cultu	re
Laboratory:	NRC/UCLouvain/Belgiu m		
	BSK-H medium,		
Medium used for culture:	complete, 6% rabbit serum		
		Number of days	
	Culture result	incubated until	
Sample number	(positive/negative)	positive	Species
1	Positive	6	B.Afzelii
	2 Negative	/	/
3	B Positive	6	B.garinii
2	Positive	6	B.Burgdorferii
.			
<u>Remarks</u> Culture was made unt			





Sample 1 : BSK-H medium does not appear optimal for bacterial growth, loss of motility (days 18)




National Reference Center Borrelia burgdorferi Serology: standard two-tiered testing algorithm versus modified two-tiered testing algorithm



Guideline	Year
French infectious disease society; SPILF	2006
IDSA	2006
British Infection association	2011
Swiss Infectious Diseases Society	2006
Canadian Public Health Laboratory Network	2006
Committee for infectious diseases and vaccinations of the German academy for pediatrics and adolescent health	2012
German Borreliosis Society	2010
EFNS	2010
Polish Society of epidemiology and infectious diseases 2015	2015
Belgian Society of Infectious Diseases and Clinical Microbiology	2016
ESGBOR	2017
NICE	2017
Rheumatology Society and German Association	2013
German Society of Hygiene and Microbiology	2017
German dermatology Society	2016
German Neurology Society	2012



Evaluation of serology workflow



Adapted from Kabyashi et al (2022). Diagnostic Testing for Lyme Disease. Infect Dis Clin N Am



Standard Two-Tiered Testing (STTT) Algorithm

• 2-Tiered

- Sensitive enzyme immunoassay (EIA) (OR immunofluorescent assay (IFA))
 - Goal: Maximize sensitivity
- <u>Standardized</u> Western immunoblot when positive or equivocal by EIA/IFA
 - Goal: Maximize specificity
- Second National Conference on Serologic Diagnosis of Lyme Disease
 - Declared as reference method in 1994...for 25 years
- Limitation
 - Challenges with immunoblot result interpretation
 - Concerns about specificity of the bands
 - Low sensitivity (35%-60%) during acute disease
 - Primarily due to limited immunoblot sensitivity




Modified Two-Tiered Testing (MTTT) Algorithm

- Food & Drug Administration (FDA)
 - July 2019: Clearance of several (4) Lyme disease serologic assays for use as second test in a Lyme disease testing algorithm
- CDC recommendations for serologic diagnosis of Lyme disease
 - August 2019: Update of 1994 guidance to allow approved EIA in place of western immunoblot assay
- Sequential or concurrent use of 2 (or more) EIA's
 - Without the use of immunoblots.



MTTTA

- MTTTA is entirely EIA-based
- 1st and 2nd tier EIAs differ in the B. burgdorferi antigens used
- Tier 1:
 - VLsE/pepC10 antigen (recombinant)
 - Total IgM/IgG
- Tier 2:
 - Whole Cell Sonicate (WCS) material from cultured Borrelia spirochetes
 - IgM and IgG separately or Total IgM/IgG





MTTTA vs STTTA

Stage of Lyme disease	% positive by the STTTA	% positive by a 2-EIA MTTTA
Erythema migrans	42%-58%	53%-67%
Early disseminated Lyme	73%-95%	85%-100%
Late Lyme	97%-100%	100%
All stages	57%73%	68%-88%

- MTTTA more sensitive vs. the STTTA across studies and EIA in patients with EM and overall
- Equivalent sensitivity during later stages of Lyme disease
- False positivity rate remains unchanged
- One study performed in Europe (Baasma et al. 2020, Netherlands) -> comparable results

PMID: 21865190 PMID: 29743307 PMID: 27558183 PMID: 32632699



MTTTA: (dis)advantages

Advantages

- Greater sensitivity in early Lyme disease
 - BUT still 'only' +/- 60% => Clinical presentation remains important
- More cost-effective and less labour intensive (vs immunoblot)
- Shorter turnaround time and less technically demanding
 - Ability for smaller laboratories to perform all stages of testing
- Easier interpretation of results (nobanding pattern)

Disadvantages

- Inability to distuingish active versus past infections
- Loss of information on specific antigen epitopes
 - Loss of insight in the extent and maturity of the antibody response and possible reinfections
- Limited research performed in European context



Immunoblot: Step 2 in STTTA

- Antibody response is evaluated against the different antigens which are separated and fixed on a solid support, generally nitrocellulose strips.
- <u>Western blot</u>: whole cell antigens with proteins separated by electrophoresis according to molecular weight
- <u>Line blot:</u> purified proteins (recombinant or mixture of native and recombinant)



Western blot

- Different guidelines (Dressler et al. 1993, CDC 1995, Engstrom 1995 et al., Hauser et al. 1999)
- USA: BBSS 297 strain from a patient with neuroborreliosis
 - IgM: at least two bands: OspC, p39 (BmpA) and p41
 - IgG: at least 5 bands (p18, OspC, p28, p30, p39, p41, p45, p58, p66 en p93)
- **Europe:** B. afzelii strain Pko (originally isolated from human erythema migrans lesion in Germany)
 - IgM: at least one band: strong p41, p17 (DbpA)
 - IgG: at least 2 bands (p14, p17, p21, OspC, p30,p39,p43, p58 and p83/100)



Line blot

- Improvement sensitivity without loss of specificity in the early disseminated stage by adding recombinant VIsE and DbpA
- Because the diversity of genospecies in Europe, combinations of recombinant antigens from strains belonging to different species
- Recently: Miniaturised immunoblots in 96-well microplate format
 - Microplate wells contain test strips that are printed with purified, pathogen-specific antigens



S

Early and late antigens


Early antigens	Early/Late antigens	Late antigens OspA (p31) p30	
<mark>OspC</mark> (p21-p25, Major outer surface lipoprotein C)	VIsE (vmp-like sequence E) Dbpa (p17-p18,		
BbK32 (Fibronectin-binding protein)	Decorin-binding protein A) OppA-2 (p58,	p66 p83/100	
Flagellin (p41)	Oligopeptide-binding protein) BmpA (p39)	p93	
	p14 p28		
	p43 p45		

Antigen	Characteristics
P41	 cross-reactivity with other spirochetes (e.g. Treponema) IgM antibodies against p41 appear very early after infection
OspC	The first detectable antibodies after infection
P17/Dbpa	Lyme arthritis



Poor specificity IgM (1)

- Isolated positive IgM: careful attention
- Specimens collected > 6 weeks after onset of symptoms -> 'false positive'
- Native dimeric '<u>Outer Surface Protein C</u>' (OspC) is the most important serological marker (sensitivity up to 90%)
 - Cultivation of this antigen is complicated, therefore recombinant Ag is used.
 - C-terminal epitope of OspC occurs in certain other human proteins/bacteria/environment
 - Lower specificity
- Same for p41 (sequence identitiy with flagellin proteins of Treponema)
- BmpA (IgM and IgG): cross-reacts with Syphilis, CMV, B19, RF



PMID: 22309852 PMID: 34937165 PMID: 37873860



Overview cross-reactivity

	p41	BmpA (p39)	VIsE	OspC
RFB	lgM+/lgG+	lgM+/lgG+	lgM+/lgG+	lgM+/lgG+
Syphilis	lgM+/lgG+	lgM+/lgG-	IgM-/IgGnd	lgM+/lgG-
Yersinia	lgM+/lgG+	lgM+/lgG+	Nd	lgM+/lgG+
EBV	lgM+/lgGnd	Nd	Nd	lgM+/lgG+
CMV	lgM+/lgG-	Nd	Nd	lgM+/lgG-
B19	Nd	IgM+/IgGnd	lgM+/lgGnd	Nd
RF	lgM-/lgG-	lgM+/lgG+	Nd	lgM-/lgG-

Nd: no data



Poor specificity IgM (2)

- Isolated positive IgM for specimens collected more than 6 weeks after the onset of the symptoms
 - considered as false positive (CDC criteria)
- 4 criteria should be sought in case IgM+, IgG-
 - I. Verification of the positivity criteria for serology
 - II. High probability of tick exposure?
 - III. Symptoms and clinical signs highly evocative of early Lyme borreliosis
 - IV. IgG seroconversion on retesting more than 4 weeks later



National Reference Center Borrelia burgdorferi

CXCL13, a biomarker for Lyme neuroborreliosis



Introduction to CXCL13

- B-cell-attracting chemokine
- B. burgdorferi induces release of CXCL13 into the CSF -> B cells are recruited to the site of infection -> B-cell enriched pleocytosis
- Promising assay
- Transportation: 2-8°C
 - **PRO**:
 - CXCL13 levels are detectable early in the disease process, days to weeks before AB production
 - CONTRA:
 - elevated in other neuroinfectious and neuroinflammatory diseases
 - Falls rapidly after start of antibiotic therapy

Pooled sensitivity	Pooled specificity
89% (95% CI 85%-93%)	96% (95% CI 92%-98%)



Study at UZ Leuven (2016-2019) for LNB

	20	16-2019		
	Confirmed (n=64)		Not Confiri (n=566)	med
	#	%	#	%
Negative < 20 pg/ml	7	10.9	488	86.2
Indeterminate 20-30 pg/ml	1	1.6	21	3.7
Positive 30-100 pg/ml	9	14.1	26	4.6
Strongly positive > 100 pg/ml	47	73.4	31	5.5



National Reference Center Borrelia burgdorferi

Take home messages



Serology is not indicated

- I. For asymptomatic patients following a tick bite, as asymptomatic seroconversion is possible, in which treatment is not indicated
- II. For the follow-up of patients with Lyme borreliosis
- III. For screening, as antibodies only reflect an exposure to Borrelia and not the disease itself
- IV. For erythema migrans



Keypoints

National Reference Center Borrelia burgdorferi



To test or not to test? Laboratory support for the diagnosis of Lyme borreliosis: a position paper of ESGBOR, the ESCMID study group for Lyme borreliosis CMI

CLINICAL

MICROBIOLOG AND INFECTIO

ESCMID ERAT

R.B. Dessau^{1, *}, A.P. van Dam², V. Fingerle³, J. Gray⁴, J.W. Hovius⁵, K.-P. Hunfeld⁶, B. Jaulhac⁷, O. Kahl⁸, W. Kristoferitsch⁹, P.-E. Lindgren¹⁰, M. Markowicz¹¹, S. Mavin¹², K. Ornstein¹³, T. Rupprecht¹⁴, G. Stanek¹¹, F. Strle¹⁵

- Patients with a typical erythema migrans should be diagnosed clinically and treated promptly without serological testing (insensitive)
- The use of Borrelia serology in patients with non-specific subjective symptoms is discouraged!!
- In patients with disease duration > 6 weeks a specific IgG response is a prerequisite, but an isolated IgM response is of no diagnostic relevance.
- Detection of antibodies to B. burgdorferi cannot discriminate between active or past infection (clinical symptoms?)





Woman 73 years old. Red-purple discoloration left ankle. Lyme serology is requested by dermatologist.

Serology:

Lyme Ig total (C6-peptide EIA): 9.0 / positive Lyme IgM blot (RecomLine) : negative Lyme IgG blot (RecomLine) : positive IgG blot: p100 -,VIsE +,p58 +,p41 +,p39 -,OspA -,OspC -,p18 +

Is there an active Lyme disease?

Yes, late manifestation of Lyme -> Acrodermatitis chronica atrophicans

In patients with late presentation of Lyme-borreliosis, such as arthritis or ACA only the detection of IgG antibodies should be considered diagnostic.



Important to complete the NRC request form

Please fill in the request form!!

Diagnosis of Lyme borreliosis is based on <u>a complete</u> diagnostic workup, including medical history with compatible clinical symptoms and possible exposure to tick bites

REFERENTIECENTRUM VOOR LYME BORRELIOSIS

GELIEVE HET STAAL SAMEN MET DIT INGEVULD FORMULIER** OP TE STUREN NA UZ Leuven, Dienst Laboratoriumgeneeskunde Accreditatiecertificaat 215-MED Herestraat 49, 3000 Leuven Tel : 016/347000 E-mail : melissa.depypere@uzleuven.be

*KLINISCHE GEGEVENS

Datum van aanvang symptomen :

Symptomen:

Erythema migrans

Arthritis

Neuroborreliose

Andere, specificeer:

*EPIDEMIOLOGISCHE GEGEVENS

Tekenbeet. Datum :
□ Vermoedelijke provincie van besmetting :

□ Behandeling reeds gestart voor staalname.

□ Vroegere Lyme borreliose. Jaar :

□ Andere epidemiologische gegevens :